Introduction#
Incyte Corporation, a biotech company based in Wilmington, Delaware, has announced that the U.S. Food and Drug Administration (FDA) has approved its new medication, Jakafi XR. This extended-release formulation allows patients to take the drug just once a day, offering a convenient alternative to the original Jakafi, which is taken twice daily.
Approved Uses#
Jakafi XR is approved for treating several serious health conditions. These include: - Adults with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. - Adults with polycythemia vera, a blood disorder, who have not responded well to or cannot tolerate hydroxyurea, a common treatment. - Adults and children aged 12 and older with steroid-refractory acute graft-versus-host disease or chronic graft-versus-host disease after failing one or two prior treatments.
Clinical Study Findings#
The FDA's decision was based on a clinical study that demonstrated that a single 55 mg Jakafi XR tablet taken once daily provides similar drug exposure levels as a 25 mg Jakafi tablet taken twice daily. This means that patients can expect similar effectiveness while simplifying their medication routine.
Safety Profile and Availability#
The safety profile of Jakafi XR is well-established, based on studies of the original Jakafi formulation. Common side effects may include low blood cell counts, bruising, dizziness, headaches, diarrhea, infections, and swelling, which can vary depending on the condition being treated. Jakafi XR is expected to be available for pharmacy orders starting May 8.
Incyte continues to show strong financial performance, with a recent report indicating total net sales of $1.104 billion for the first quarter of 2026, exceeding analysts' expectations. This positive financial outlook reflects investor confidence in the company's product pipeline and growth potential.